01Identity
What is administered?
Living cells, mixed tissue, an isolated fraction and a cell-free secretome are different products.
Stem Cell-Based Approaches · Hair and Scalp
Stem Cell-Based Approaches · Hair and Scalp
Stem Cell-Based Approaches
A stem-cell label can refer to very different materials: living cultured cells, isolated cell populations, minimally processed tissue, mixed autologous fractions or even cell-free products. These must not be treated as one therapy.
Tissue-derived preparations, SVF, microfat, nanofat, micrografts and exosome products are not automatically stem-cell products. No approach is presented as creating new follicles or guaranteeing lasting growth.
Quick Orientation
Four distinctions before a cellular claim
Define the product before discussing a possible effect.
Source tissue, cell population, processing, intended function and regulatory class must be explicit.
02Source
Where did it come from?
Autologous or donor origin, tissue source, collection and donor controls are recorded.
03Manufacture
How was it processed?
Washing, digestion, selection, culture, expansion, storage and transport alter identity and risk.
04Status
What is the legal class?
Classification depends on product, manipulation, intended function, route and country.
Cell and Tissue Identity
Cells · tissue preparations · cell-free products
A shared biological origin does not make products interchangeable.
Living cellular medicinal products, tissue grafts, mixed autologous preparations and extracellular-vesicle products have different quality, safety and regulatory questions.
What a product review can do
- Identify cell or tissue source, processing, composition and intended function
- Separate autologous, donor-derived, cultured and cell-free preparations
- Evaluate route, traceability and evidence for one clinical target
- Determine whether a product-specific regulatory pathway applies
What the label cannot prove
- Rename every tissue fraction as stem-cell treatment
- Assume autologous material is minimally manipulated or risk-free
- Transfer laboratory differentiation findings to scalp outcomes
- Promise new follicles, regeneration, density or permanent growth
If the administered material, cell identity, processing and regulatory status cannot be documented, a meaningful benefit-risk assessment is not possible.
Medical Suitability
Diagnosis, product and donor site
Five questions stand before any cell-based consideration.
Photographs may describe visible loss but cannot establish diagnosis, cell-product quality, donor-site suitability or regulatory classification.
- 01
Confirm the diagnosis
Pattern loss is separated from active inflammatory, scarring, sudden and other conditions.
- 02
Define the material
Cell type, tissue source, autologous or donor origin, viability, purity and accompanying components are stated.
- 03
Map the processing
Collection, manipulation, culture, expansion, storage, transport and release testing are reviewed.
- 04
Assess both sites
The scalp target and any harvest site require separate examination, consent and risk assessment.
- 05
Check status and alternatives
Authorisation, trial context, established care, observation and no treatment are compared.
Product Pathway
Harvest · processing · release
Every manipulation belongs to the clinical identity.
The chain from donor or harvest site to the administered product must remain traceable and appropriate to its regulatory class.
01Collection
Source and donor controls
Autologous or donor tissue is collected under a defined purpose with identity and safety controls.
- Examine and consent the source site
- Record donor and material identity
- Define transport and handling conditions
02Processing
Cells, tissue and manipulation
Isolation, digestion, selection, culture or expansion can change composition, function and classification.
- Describe every processing step
- Measure viability and relevant impurities
- Prevent contamination and mix-ups
03Release
Product status and route
A product needs documented release, storage, intended function and one justified route before clinical use.
- Verify batch and release criteria
- Confirm authorisation or trial framework
- Link route to safety follow-up
A same-day, autologous or minimally processed claim does not by itself determine product class, safety, clinical effectiveness or permission to use it.
Evidence and Limits
Experimental rationale · product-specific human evidence
Cell biology does not establish a clinical hair outcome.
Human evidence for scalp cell-based products remains heterogeneous. Products, processing, comparators and endpoints differ, and long-term safety data are limited.
Do not infer new follicles
Laboratory differentiation or signalling does not show clinically created human follicles.
Keep preparations separate
Evidence for cultured cells cannot be transferred to SVF, micrografts, fat or secretome products.
Check study governance
A regulated clinical trial is different from routine marketing of an unapproved product.
Leave long-term questions open
Persistence, abnormal tissue effects, tumour risk and durable benefit need product-specific follow-up.
No class-wide claim of regeneration, superiority, permanent growth or a standard session plan is supported.
Individual Plan
Classification before intervention
The valid outcome may be not to use a cellular product.
Only a defined diagnosis, product, lawful pathway, acceptable risk and measurable endpoint could justify further consideration.
Document the clinical need
Diagnosis, scalp findings, baseline images and established alternatives are recorded.
Complete product classification
Source, cells, tissue, manipulation, intended function, route and status are reviewed.
Define governance
If applicable, authorisation, trial oversight, consent, traceability and long-term follow-up are confirmed.
Use a clear stop decision
Unclear identity, unjustified risk or inadequate evidence ends the pathway rather than creating a package.
Course and Follow-Up
Procedure safety · product surveillance · clinical endpoint
Cellular products may require longer safety observation.
Harvest-site healing, target-site response, systemic events and the stated hair endpoint are followed on separate timelines.
- 01Early
Early procedure review
Pain, bleeding, swelling, infection and harvest- or injection-site healing are documented.
- 02Safety
Product surveillance
Inflammatory, immune, neurological, vascular or unexpected tissue effects are linked to the exact product.
- 03Outcome
Hair endpoint review
Only pre-defined, comparable clinical measures are used to assess the scalp question.
- 04Long term
Longer follow-up
Persistence and delayed adverse effects may require monitoring beyond the visible hair-response window.
Risks and Alternatives
Living products and tissue manipulation add uncertainty
Risk depends on cells, processing, route and intended function.
Infection, contamination, immune reaction, abnormal tissue formation, vascular or neurological injury and donor-site harm require product-specific consideration.
01Cell or tissue
Product
Misidentification, contamination, variable viability, impurities or unintended biological behaviour may occur.
02Route
Procedure
Harvest, injection or implantation may cause bleeding, infection, scarring and anatomical injury.
03Choice
Alternative
Authorised medicines, observation, a defined autologous procedure, transplantation planning or no treatment may be safer.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Traceability, adverse-event reporting and an appropriate long-term contact pathway are necessary whenever a regulated cellular product is considered.
Istanbul and Follow-Up
Governance must travel with the patient
A cellular procedure cannot be reduced to a treatment-day visit.
Classification, consent, harvest-site care, product traceability and later safety review must remain workable across borders.
01Before travel
Prepare the clinical record
Diagnosis history, medicines, previous procedures and relevant reports are organised.
02In Istanbul
Verify the full pathway
Product, processing, status, sites, risks, alternatives and follow-up are reviewed in person.
03Treatment day
Retain traceability
Any regulated use would document source, processing, product identity, route and immediate findings.
04After return
Maintain longer contact
Source- and target-site recovery, safety concerns and the agreed endpoint need an accessible plan.
The Doctor Aslan Approach
Cells, tissue and claims kept separate
The word stem cell never replaces product classification.
Living cellular products, tissue-derived preparations and cell-free approaches are evaluated under their own identities, risks and evidence boundaries.
Identify what is given
Cell type, tissue, viability, purity and accompanying material are named.
Map every manipulation
Harvest, separation, culture, expansion, storage and route remain visible.
Protect the evidence boundary
No laboratory mechanism becomes a promise of new follicles or regeneration.
Accept no treatment
An unclear or unjustified pathway ends with a reasoned decision not to proceed.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about cellular and tissue-derived approaches; no personal diagnosis, protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Stem Cell-Based Approaches?+
Stem Cell-Based Approaches is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Stem Cell-Based Approaches?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Classify the material · examine the clinical need